TGFB1 and neoplasm: The use of cell-specific Lrrc32 KO mice provided evidence that targeting Garp on Tregs, but not on platelets, with a blocking anti-GARP:TGF-β1 antibody induced tumor regression and overcame resistance to PD1 blockade in tumor-bearing mice [40].